A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases

Abstract

[...]some patients may exhibit higher risks of adverse effects, such as myopathy and rhabdomyolysis, particularly with cerivastatin. [...]balancing efficacy and risk is crucial for protecting patient health [5]. Selection Criteria Studies were included if they met the following inclusion criteria: (1) RCTs, (2) statin comparisons (vs. placebos and other drugs), (3) detailed patient information, (4) clear statin names/doses, (5) follow-up period of at least 1 month, and (6) > 30 participants per group. Judgments were “low,” “some concerns,” or “high” at the domain level, with an overall judgment based on criteria [8]. [...]it employs a macroenabled Excel file, released by the revised version of RoB2 on August 22, 2019, as an assessment tool [9]. Study (author, year) Country/region, population Intervention (per day) Sample size Mean age (mean ± SD, year) Male sex (%) Duration Outcomes Tsujita 2023 Japan Patients with hypercholesterolemia Pitavastatin 2 mg Pitavastatin 4 mg 72 72 56.4±9.5 55.7±8.5 34 (47.2%) 34 (47.2%) 12 weeks Adverse events Adverse drug reactions ALT/AST increased CK increased > 10× ULN Jeong 2022 Korea Patients with hypercholesterolemia Pitavastatin 2 mg Pitavastatin 4 mg 69 70 64.1±7.9 62.9±9.9 44 (63.8%) 43 (61.4%) 8 weeks Adverse events Adverse drug reactions ALT/AST increased > 3× ULN Musculoskeletal and connective tissue disorders Arthralgia Myopathy Gastrointestinal disorders Rhee 2020 Korea Patients with hypertension and hypercholesterolemia Rosuvastatin 20 mg 91 61.74±9.75 65 (71.43%) 8 weeks Adverse drug reactions CK increased Moroi 2020 Japan Patients with hypercholesterolemia Pitavastatin 2 mg Atorvastatin 10 mg 312 310 65.3±10.1 65.4±9.4 168 (53.8%)